Gulf Scientific Corporation (GSC), a prominent provider of specialized laboratory solutions throughout the Gulf Cooperation Council (GCC), is pleased to announce a new partnership with Velsera, a trailblazer in the field of precision medicine platforms headquartered in the USA. This collaboration facilitates GSC’s representation of Velsera in the Kingdom of Saudi Arabia, Qatar, and Kuwait, representing a key expansion of its Life Science Division.
A central element of this partnership is the introduction of the Clinical Genomics Workspace (CGW), a dynamic tool designed to optimize Next-Generation Sequencing (NGS) workflows.
Additionally, the Seven Bridges Platform, a robust, secure cloud-based system, will come to the region. This platform significantly enhances the speed and efficiency of processing biomedical data, supporting a broad spectrum of drug discovery activities.
These state-of-the-art offerings set Gulf Scientific Corporation at the forefront of the life sciences industry in the region, advancing laboratory capabilities and fostering scientific innovation. The partnership with Velsera underscores GSC’s dedication to enhancing its Life Science Division with cutting-edge technologies and comprehensive services, ensuring its position as a leader in the provision of high-quality, advanced laboratory solutions throughout its markets.
About Gulf Scientific Corporation:
Gulf Scientific Corporation, headquartered in Dubai – United Arab Emirates, is a leading provider of laboratory solutions in the Gulf Cooperation Council (GCC). With regional offices across major Gulf cities, GSC is dedicated to supplying innovative solutions and exceptional services in the fields of analytical, material, and life sciences. The company has established strategic partnerships with global market leaders to bring the latest technologies and advancements to the scientific community in the GCC. For more information, visit [GSC’s website].
About Velsera:
Velsera is dedicated to transforming patient care by supporting physicians and researchers in making informed therapeutic decisions. With over a decade of innovation in clinical software and genetic disease analysis, Velsera focuses on oncology and rare hereditary diseases, aiding in precise treatment delivery.